Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Einar Svarstad

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Transplantation|October 28, 2003
C2 monitoring in maintenance renal transplant recipients: is it worthwhile?Karsten Midtvedt, Per Fauchald, Stein Bergan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 20, 2017
Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry DiseaseRannveig Skrunes, Camilla Tøndel, Sabine Leh, et al.
IEEE Transactions on Bio-Medical Engineering|November 8, 2018
In Vivo Detection of Chronic Kidney Disease Using Tissue Deformation Fields From Dynamic MR ImagingErlend Hodneland, Eirik Keilegavlen, Erik A Hanson, et al.
Molecular Genetics and Metabolism Reports|March 4, 2022
Reduced α-galactosidase A activity in zebrafish (<i>Danio rerio)</i> mirrors distinct features of Fabry nephropathy phenotypeHassan O A Elsaid, Jessica Furriol, Maria Blomqvist, et al.
Kidney International|July 7, 2023
Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposingNicolas Delaleu, Hans-Peter Marti, Philipp Strauss, et al.
JIMD Reports|September 17, 2014
Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-upL van der Tol, David Cassiman, Gunnar Houge, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Molecular Genetics and Metabolism|September 5, 2014
Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosisLinda van der Tol, Einar Svarstad, Alberto Ortiz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 17, 2009
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)Agnes B Fogo, Leif Bostad, Einar Svarstad, et al.
BMJ Open|October 11, 2020
Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiativeDerralynn A Hughes, Patricio Aguiar, Patrick B Deegan, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Transplantation|October 28, 2003
C2 monitoring in maintenance renal transplant recipients: is it worthwhile?Karsten Midtvedt, Per Fauchald, Stein Bergan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 20, 2017
Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry DiseaseRannveig Skrunes, Camilla Tøndel, Sabine Leh, et al.
IEEE Transactions on Bio-Medical Engineering|November 8, 2018
In Vivo Detection of Chronic Kidney Disease Using Tissue Deformation Fields From Dynamic MR ImagingErlend Hodneland, Eirik Keilegavlen, Erik A Hanson, et al.
Molecular Genetics and Metabolism Reports|March 4, 2022
Reduced α-galactosidase A activity in zebrafish (<i>Danio rerio)</i> mirrors distinct features of Fabry nephropathy phenotypeHassan O A Elsaid, Jessica Furriol, Maria Blomqvist, et al.
Kidney International|July 7, 2023
Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposingNicolas Delaleu, Hans-Peter Marti, Philipp Strauss, et al.
JIMD Reports|September 17, 2014
Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-upL van der Tol, David Cassiman, Gunnar Houge, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Molecular Genetics and Metabolism|September 5, 2014
Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosisLinda van der Tol, Einar Svarstad, Alberto Ortiz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 17, 2009
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)Agnes B Fogo, Leif Bostad, Einar Svarstad, et al.
BMJ Open|October 11, 2020
Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiativeDerralynn A Hughes, Patricio Aguiar, Patrick B Deegan, et al.
Pageof 7